The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients

Background and Objectives: On 24 March 2020, the United States Food and Drug Administration (FDA) announced the approval of convalescent plasma therapy for critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as an emergency investigational new drug. This pilot s...

Descripción completa

Detalles Bibliográficos
Autores principales: Tirnea, Livius, Bratosin, Felix, Vidican, Iulia, Cerbu, Bianca, Turaiche, Mirela, Timircan, Madalina, Margan, Madalin-Marius, Marincu, Iosif
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998120/
https://www.ncbi.nlm.nih.gov/pubmed/33799535
http://dx.doi.org/10.3390/medicina57030257

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998120/
https://www.ncbi.nlm.nih.gov/pubmed/33799535
http://dx.doi.org/10.3390/medicina57030257

Ejemplares similares